The capability of decreasing the expression of selected target integrins by pharmacological treatment is quite intriguing as α5β1 integrin, together with concomitant EGFR activation, is required for mutated p53 driven enhancement of cancer cell motility (24). The gene discussed is TP53; the disease is cancer.